Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
4.940
-0.100 (-1.98%)
At close: Aug 29, 2025, 4:00 PM
5.00
+0.06 (1.21%)
After-hours: Aug 29, 2025, 7:57 PM EDT
Vir Biotechnology Stock Forecast
Stock Price Forecast
The 9 analysts that cover Vir Biotechnology stock have a consensus rating of "Strong Buy" and an average price target of $28.44, which forecasts a 475.71% increase in the stock price over the next year. The lowest target is $12 and the highest is $110.
Price Target: $28.44 (+475.71%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Vir Biotechnology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 4 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 8 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Hold → Strong Buy Upgrades $12 → $14 | Hold → Strong Buy | Upgrades | $12 → $14 | +183.40% | Aug 27, 2025 |
| Raymond James | Raymond James | Buy Initiates $12 | Buy | Initiates | $12 | +142.91% | Jul 11, 2025 |
| Needham | Needham | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +183.40% | May 22, 2025 |
| Needham | Needham | Strong Buy Maintains $19 → $14 | Strong Buy | Maintains | $19 → $14 | +183.40% | May 12, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $28 → $21 | Strong Buy | Maintains | $28 → $21 | +325.10% | Apr 17, 2025 |
Financial Forecast
Revenue This Year
11.99M
from 74.21M
Decreased by -83.84%
Revenue Next Year
13.15M
from 11.99M
Increased by 9.65%
EPS This Year
-3.33
from -3.83
EPS Next Year
-2.95
from -3.33
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 38.9M | 31.1M | |||
| Avg | 12.0M | 13.1M | |||
| Low | 4.6M | 4.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -47.6% | 159.7% | |||
| Avg | -83.8% | 9.7% | |||
| Low | -93.8% | -61.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.01 | -2.52 | |||
| Avg | -3.33 | -2.95 | |||
| Low | -3.76 | -3.47 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.